Why Oncology Analytics?

Over the past five years, U.S. anti-cancer drug costs have increased to $50B annually, driven primarily by availability and favorable reimbursement of new medicines. By 2021, global cancer drugs expenditures are expected to exceed $147B annually.

The Oncology Landscape

As cancer treatment options expand and costs continue to rise, health plans, providers and patients face a collective challenge when trying to determine the best course of treatment.

Health PlanToday’s innovation-driven climate puts health plans in the difficult position of determining how best to judge the cost/value ratio for the constant influx of new and emerging cancer treatments. As a result, health plans must find ways to build scalable, internal oncology-specific expertise and processes that can quickly evaluate treatment options across a multitude of cancer diagnoses.

ProviderDrug and treatment innovations across cancer types, such as immunotherapy, hold great promise for the future evolution of cancer treatment and care. However, innovation can also be disruptive, as the growing number of treatment options, combinations, and additional lines of therapy simultaneously increase the complexity the oncologist faces in making an evidence-based determination for how to best treat a patient’s cancer.

PatientsThe changing oncology landscape in the U.S. healthcare market has significant consequences for patients – the people most impacted by health plan and provider decisions. Depending on the patient’s insurance plan, the rising cost of cancer treatment may significantly increase out-of-pocket costs, which can potentially lead to reduced adherence to their care plan.

Why Oncology Analytics?

Evidence Based. Patient First.

Our founder, Dr. Marc Fishman, a hematologist, oncologist and patient advocate, recognized that the rising costs and complexity of cancer treatment were compromising the ability for oncologists to make comprehensive, evidenced-based decisions for their patients’ treatment.

Oncology Analytics believes that when building the optimal treatment plan, cost and quality are not mutually exclusive and that doing the “right thing” and putting the patient in a position to achieve the best possible outcome requires a consistent process for evaluating the efficacy, toxicity, and costs of treatment options.

Our board-certified oncologists, radiation oncologists, hematologists, and pharmacists have operationalized protocols that cover all cancer diagnoses. These protocols are based on evidence-based guidelines from nationally recognized authorities such as NCCN, ASCO, and others.

Oncology Analytics understands the complexity involved in the management of cancer treatment options caused by the rapid pace of research and new drug introductions that is changing the oncology landscape on a daily basis. We are committed to the ongoing review and analysis of oncology treatments, their outcomes, and adverse effects to ensure that all cancer treatment recommendations provide the patient with the opportunity to achieve the best possible outcome.